This proof-of-principle physiologic study in hypertensive Black LSD1 risk allele carriers testing the hypothesis that reductions in blood pressure will be greater with a genetically-driven anti-hypertensive approach (mineralocorticoid receptor antagonist, eplerenone) compared to a non-specific approach (amlodipine). 56 participants will be enrolled in a 12-week randomized, double-blind, active controlled, outpatient study to assess whether eplerenone (LSD1 specific treatment) proves superior in 24-hr ambulatory systolic blood pressure reduction than amlodipine (non-specific treatment). Participants will be randomized to either eplerenone 50mg or amlodipine 2.5mg with escalations in dose of study drug every 4 weeks if the participant’s blood pressure is > 140/90.
Study Name: Role of LSD1 in Hypertension in Blacks
Status: Not yet recruiting
Conditions: Hypertension, Mineralocorticoid Excess
Interventions: Eplerenone, Amlodipine
Locations: Brigham and Women’s Hospital, Boston, MA, USA
Study link: https://clinicaltrials.gov/ct2/show/NCT04840342
To search for other studies by topic, location, or status, go to our Clinical Studies page.